You are viewing the site in preview mode
Skip to main content
|
Characteristic
|
Patients treated with statins (n=1509)
|
Patients not treated with statins (n=6731)
|
p-value
|
|---|
|
Mean age, years
|
66.5
|
54.9
|
<0.01
|
|
Men, n (%)
|
847 (56.1)
|
3650 (54.2)
|
0.18
|
|
Mean BMI, kg/m2
|
29.3
|
27.8
|
<0.01
|
|
Creatinine clearance, n (%)
| | |
<0.01
|
|
<50 ml/min
|
207 (13.7)
|
442 (6.6)
| |
|
50–<80 ml/min
|
515 (34.1)
|
1500 (22.3)
| |
|
≥80 ml/min
|
775 (51.4)
|
4736 (70.4)
| |
|
Missing
|
12 (0.8)
|
53 (0.8)
| |
|
Planned treatment duration, n (%)
| | |
<0.01
|
|
3 months
|
75 (5.0)
|
580 (8.6)
| |
|
6 months
|
858 (56.9)
|
4056 (60.3)
| |
|
12 months
|
576 (38.2)
|
2095 (31.1)
| |
|
Index event, n (%)
| | |
<0.01
|
|
Only DVT
|
489 (32.4)
|
2880 (42.8)
| |
|
PE ± DVT
|
1012 (67.1)
|
3783 (57.2)
| |
|
Index event not confirmed or evaluable
|
8 (0.5)
|
68 (1.0)
| |
|
Immobilization at randomization, n (%)
|
232 (15.4)
|
1051 (15.6)
|
0.82
|
|
Active cancer at randomization, n (%)
|
76 (5.0)
|
352 (5.2)
|
0.76
|
|
Ischemic heart disease, n (%)
|
410 (27.2)
|
229 (3.4)
|
<0.01
|
|
Peripheral arterial disease, n (%)
|
39 (2.6)
|
29 (0.4)
|
<0.01
|
|
Ischemic cerebrovascular disease, n (%)
|
53 (3.5)
|
45 (0.7)
|
<0.01
|
|
ASA use at baseline, n (%)
|
387 (26.5)
|
337 (5.0)
|
<0.01
|
|
ASA stopped at randomization, n
|
85
|
122
| |
|
Hypertension, n (%)
|
1052 (69.7)
|
2181 (32.4)
|
<0.01
|
|
Diabetes, n (%)
|
392 (26.0)
|
512 (7.6)
|
<0.01
|
- ASA, acetylsalicylic acid; BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; VKA, vitamin K antagonist.
- Data from EINSTEIN DVT and EINSTEIN PE combined, safety population.
